Neurotech bounces back from FDA rejection with new NTI164 baseline study
Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from…
Neurotech International Limited (ASX:NTI)
About Neurotech International Limited
Key Information
NTI In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 17/12/2024 | Notice of Expiry of Listed Options | 150.08KB | 242 |
| 12/12/2024 | Becoming a substantial holder | 266.02KB | 350 |
| 06/12/2024 | Change of Director's Interest Notice | 177.41KB | 514 |
| 02/12/2024 | Resignation of Joint Company Secretary | 83.84KB | 304 |
| 02/12/2024 | Secondary Trading Notice | 84.39KB | 260 |
| 02/12/2024 | Application for quotation of securities - NTI | 15.79KB | 221 |
| 26/11/2024 | Price Sensitive PS Neurotech Receives US ODD in Rett Syndrome | 127.66KB | 7.2K |
| 25/11/2024 | Price Sensitive PS NTI Receives Ethics Approval to Commence Human PK Study | 129.34KB | 2.4K |